Gilead Sciences, Inc. (GILD) Gains Attention as Livdelzi Demonstrates Long-Term Efficacy and Safety
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In . Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued stocks to invest in. TheFly reported on May 27…
We recently compiled a list of the 11 Most Undervalued Pharma Stocks to Invest In . Gilead Sciences, Inc. (NASDAQ:GILD) is one of the most undervalued
Read Full Story at Yahoo Finance →Why This Matters
The long-term efficacy and safety data for Livdelzi (Gilead’s investigational NASH therapy) could redefine the company’s strategic positioning in a $30 billion-plus liver disease market. Investors are increasingly scrutinizing pharma stocks for undervalued assets with blockbuster potential, and Gilead’s progress could validate its transformation from an HIV and hepatitis giant into a diversified metabolic health leader.
Background Context
Gilead’s dominance in antiviral therapies has masked its struggles to replicate that success in other disease areas, particularly NASH, where competitors like Intercept Pharmaceuticals and Madrigal Pharmaceuticals have faced regulatory setbacks. The company’s $1.5 billion bet on Livdelzi in 2022 signaled a pivot toward metabolic disorders, but regulatory skepticism remains high after recent FDA rejections in the space.
What Happens Next
If Livdelzi’s Phase 3 data meets expectations, it could accelerate Gilead’s entry into the NASH market ahead of a crowded 2025-2026 approval window. Failure, however, might reinforce investor doubts about the company’s ability to diversify beyond its core franchises. Analysts will be watching closely for FDA feedback on trial endpoints and long-term safety metrics.
Bigger Picture
This case reflects a broader trend of “old guard” pharma companies—flush with cash but facing patent cliffs—pursuing high-risk, high-reward metabolic assets to offset revenue declines. The NASH market’s volatility highlights the tension between innovation and regulatory caution, a dynamic that could reshape investor priorities across the biotech landscape.
